Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations

Archive ouverte

Reincke, Martin | Albani, Adriana | Assie, Guillaume | Bancos, Irina | Brue, Thierry | Buchfelder, Michael | Chabre, Olivier | Ceccato, Filippo | Daniele, Andrea | Detomas, Mario | Di Dalmazi, Guido | Elenkova, Atanaska | Findling, James | Grossman, Ashley | Gomez-Sanchez, Celso | Heaney, Anthony | Honegger, Juergen | Karavitaki, Niki | Lacroix, Andre | Laws, Edward | Losa, Marco | Murakami, Masanori | Newell-Price, John | Pecori Giraldi, Francesca | Pérez‐rivas, Luis | Pivonello, Rosario | Rainey, William | Sbiera, Silviu | Schopohl, Jochen | Stratakis, Constantine | Theodoropoulou, Marily | van Rossum, Elisabeth | Valassi, Elena | Zacharieva, Sabina | Rubinstein, German | Ritzel, Katrin

Edité par CCSD ; Oxford Univ. Press -

International audience. Background Corticotroph tumor progression (CTP) leading to Nelson’s syndrome (NS) is a severe and difficult-to-treat complication subsequent to bilateral adrenalectomy (BADX) for Cushing’s disease. Its characteristics are not well described, and consensus recommendations for diagnosis and treatment are missing. Methods A systematic literature search was performed focusing on clinical studies and case series (≥5 patients). Definition, cumulative incidence, treatment and long-term outcomes of CTP/NS after BADX were analyzed using descriptive statistics. The results were presented and discussed at an interdisciplinary consensus workshop attended by international pituitary experts in Munich on October 28, 2018. Results Data covered definition and cumulative incidence (34 studies, 1275 patients), surgical outcome (12 studies, 187 patients), outcome of radiation therapy (21 studies, 273 patients), and medical therapy (15 studies, 72 patients). Conclusions We endorse the definition of CTP-BADX/NS as radiological progression or new detection of a pituitary tumor on thin-section MRI. We recommend surveillance by MRI after 3 months and every 12 months for the first 3 years after BADX. Subsequently, we suggest clinical evaluation every 12 months and MRI at increasing intervals every 2–4 years (depending on ACTH and clinical parameters). We recommend pituitary surgery as first-line therapy in patients with CTP-BADX/NS. Surgery should be performed before extrasellar expansion of the tumor to obtain complete and long-term remission. Conventional radiotherapy or stereotactic radiosurgery should be utilized as second-line treatment for remnant tumor tissue showing extrasellar extension

Consulter en ligne

Suggestions

Du même auteur

Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension

Archive ouverte | Fallo, Francesco | CCSD

International audience

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Archive ouverte | Ho, Ken | CCSD

International audience. Abstract The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with ...

High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.

Archive ouverte | Tichomirowa, Maria A | CCSD

International audience. BACKGROUND: Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause aggressive pituitary adenomas in young patients, usually in the setting of familial isolated pituitary...

Chargement des enrichissements...